Last reviewed · How we verify
gp96
At a glance
| Generic name | gp96 |
|---|---|
| Also known as | Heat Shock, HSPPC-96 |
| Sponsor | Cure&Sure Biotech Co., LTD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Anti-cancer DC Cell Vaccination to Treat Solid Tumors (PHASE1)
- A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (PHASE1)
- GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma (PHASE1, PHASE2)
- A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 (PHASE2)
- A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT (PHASE1, PHASE2)
- A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (PHASE2)
- GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gp96 CI brief — competitive landscape report
- gp96 updates RSS · CI watch RSS
- Cure&Sure Biotech Co., LTD portfolio CI